Cargando…

Diagnostic Dilemma of Elevated FGF23 in a Patient With Osteomalacia: A Case Report

Introduction: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome due to FGF23 hypersecretion. It is mostly seen with benign mesenchymal tumors. Establishing the diagnosis could be challenging due to occult nature of the disease. Case: A 54-year-old female presented with right thigh a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bulut, Aysegul, Pena, Samara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Bone and Mineral Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089278/ http://dx.doi.org/10.1210/jendso/bvab048.386

Ejemplares similares

MON-502 It's Not Always Osteoporosis: FGF-23 Induced Osteomalacia
por: Bello Segura, Manuel, et al.
Publicado: (2019)

SAT-385 A Normal FGF23 Does Not Preclude Tumor Induced Osteomalacia (TIO)
por: Nandam, Neeharika, et al.
Publicado: (2020)

SUN-364 Enthesophytes Are a Common Feature of FGF23-Mediated Hypophosphatemia Due to Tumor-Induced Osteomalacia
por: Gafni, Rachel Ilana, et al.
Publicado: (2020)

Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report
por: Oe, Yuki, et al.
Publicado: (2021)

Severe Hypophosphatemia and Elevated FGF23 Level Following Zoledronic Acid Infusion
por: Betlachin, Anna, et al.
Publicado: (2021)

SAT-362 A Bone to Pick with FGF23
por: Soliman, Peter, et al.
Publicado: (2020)

Sternal Phosphaturic Mesenchymal Tumor-Induced Osteomalacia, Diagnosis and Management: A Case Report
por: Adeyemo, Mopelola Adetola, et al.
Publicado: (2021)

Tumor Induced Osteomalacia in Patients With Metastatic Prostate Cancer: Case Report and Literature Review
por: Khadilkar, Arjun, et al.
Publicado: (2021)

THU464 An Uncommon Case Of Adult-Onset Hypophosphatemic Osteomalacia
por: Lockhart, Paola M, et al.
Publicado: (2023)

PSAT223 A Delayed Diagnosis of Oncogenic Osteomalacia Presenting with Bone Pain, Muscle Weakness and Elevated Alkaline Phosphatase
por: Gastelum, Alheli Arce, et al.
Publicado: (2022)

Successful Medical Management of a Non-Localising Case of Tumour-Induced Osteomalacia
por: Shan Hoong, Caroline Wei, et al.
Publicado: (2021)

MON-501 A Hemangioma Causing Tumor Induced Osteomalacia
por: Chinnakotla, Venkata Sai Bhavana, et al.
Publicado: (2019)

MON-500 A Case of Tumor-Induced Osteomalacia Caused by Metastatic Prostate Cancer
por: Rahman, Wedad, et al.
Publicado: (2019)

Severe Osteomalacia and Fractures Secondary to Vitamin D Deficiency
por: Mathew, Justin, et al.
Publicado: (2021)

THU440 A Case Of Osteomalacia In A Young Adult Female With Premature Ovarian Insufficiency
por: Kasimoglu, Ismail Hakki, et al.
Publicado: (2023)

THU462 Clinical Features & Management Of FGF23 Secreting Tumors: Series Of 40 Clinical Cases
por: Gronskaia, Sofya, et al.
Publicado: (2023)

SAT-337 Ga-DOTATATE and Tumor Induced Osteomalacia: Finding the Culprit Lesion
por: Berman, Jessica, et al.
Publicado: (2020)

MON-352 When Osteoporosis Does Not Make Sense: Tumor-Induced Osteomalacia
por: Techathaveewat, Pawarid, et al.
Publicado: (2020)

Tumor Induced Osteomalacia - Long Term Medical Treatment When Surgery Is Risky
por: Levy, Shiri, et al.
Publicado: (2021)

MON-364 Severe Postoperative Encephalopathy in a Patient with Oncogenic Osteomalacia and Neurofibromatosis Type 1
por: Sarkar, Sauradeep, et al.
Publicado: (2020)

ODP125 Soft Bones in Crohn's: Tumor-induced osteomalacia and inflammatory bowel disease
por: Habbsa, Samima, et al.
Publicado: (2022)

SAT-LB085 First Report of Burosumab (Anti-FGF23 Monoclonal Antibody) for Rickets Complicating HRAS-Associated Cutaneous Skeletal Hypophosphatemia Syndrome
por: Smith, Pamela, et al.
Publicado: (2019)

MON-499 Tumor Induced Osteomalacia: (68)Ga-DOTATATE PET/CT Scan For Localization
por: Thangavelu, Thiyagarajan, et al.
Publicado: (2019)

OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome
por: Jan De Beur, Suzanne, et al.
Publicado: (2019)

OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome
por: Carpenter, Thomas O, et al.
Publicado: (2020)

THU465 Significant Improvement In Bone Mineral Density Following Treatment For Tumor Induced Osteomalacia
por: McHan, Lara C, et al.
Publicado: (2023)

SUN-345 Use of Anti-FGF23 Monoclonal Antibody in the Treatment of Children and Adolescents with X-Linked Hypophosphatemic Rickets
por: Cassinelli, Hamilton Raul, et al.
Publicado: (2020)

MON-353 Tumor-Induced Osteomalacia from a Hypervascular Thoracic Paraspinal Mass: Challenges in Diagnosis and Management
por: Perez, Paola M, et al.
Publicado: (2020)

SUN-359 Antenatal Oral Iron Supplementation, FGF23 and Bone Metabolism in Kenyan Women and Their Offspring: A Randomised Controlled Trial
por: Braithwaite, Vickie S, et al.
Publicado: (2020)

THU393 An Internal NPT2A Cryptic PDZ Motif Is A Novel Regulator of PTH- And FGF23-sensitive Phosphate Transport
por: Sneddon, Bruce W, et al.
Publicado: (2023)

MON-504 Osteomalacia During Pregnancy: Are Preventive Measures Enough to Avoid Future Fractures and Fetal Complications?
por: Pujals Kury, Jean, et al.
Publicado: (2019)

SUN-LB093 Change in Bone Mineral Density over One Year Was Not Associated with FGF-23 in Patients New to Dialysis
por: Roy, Neil, et al.
Publicado: (2019)

Response of Severe Osteomalacia to High Dose Vitamin D3 Replacement in a Patient With Ulcerative Colitis and Liver Transplantation on Immunosuppressive Therapy
por: Azmath, Misbah, et al.
Publicado: (2021)

PSAT218 Technetium 99m-Methyl Diphosphonate (99mTc MDP) Radioguided Surgery in Patient With Tumor-Induced Osteomalacia (TIO)
por: Khan, Sara A, et al.
Publicado: (2022)

PSAT173 Weekly Supplementation with Vitamin D3 reduces 1,25(OH)2 vitamin D3 Measured by Mass Spectrometry, and increases Fibroblast-like growth factor 23 (FGF23) in Individuals with and without Primary Hyperparathyroidism (PHPT)
por: Sidana, Shivani, et al.
Publicado: (2022)

MON-LB087 Synthesis of Osteocyte-Derived Phosphaturic Hormone FGF23 via IP3/PKC Signaling Downstream of the Extra-Large Gα Subunit (XLαs)
por: He, Qing, et al.
Publicado: (2019)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 Study
por: Carpenter, Thomas, et al.
Publicado: (2022)

PSAT182 Dilemmas in the Diagnosis and Management of Osteoporosis in a patient with Alkaptonuria: Successful Treatment with Teriparatide
por: Ebrahim, Ismail, et al.
Publicado: (2022)

OR23-01 The Nonredundant Role Of Beta-Amyloid In Mediating Tonic PTH Secretion In Physiological And Pathological States
por: Tu, Chia-Ling, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mbv5e15m3v99140q3k2kqb4o82